

#339

Outcomes of Cretostimogene Grenadenorepvec in Heavily Pre-Treated and Second-Line High-Risk BCG-Unresponsive Non-Muscle Invasive Bladder Cancer with Carcinoma in Situ: Analysis from BOND-003 Cohort C

Mark D. Tyson, MD, MPH;^{1*} Shreyas S. Joshi, MD;^{2*} Trinity J. Bivalacqua, MD, PhD;^{*} and Gary D. Steinberg, MD;⁴
¹Department of Urology, Mayo Clinic, Phoenix, AZ; ²Department of Urology, Emory University School of Medicine, Atlanta, GA;
³Department of Urology, University of Pennsylvania, Philadelphia, PA; ⁴GDS Consulting, Chicago, IL




BACKGROUND

- Considerable unmet need exists for effective, well-tolerated bladder-sparing treatment options for patients with HR BCG-UR NMIBC with CIS¹
- Patients who progress despite BCG and an additional intervening therapy represent a distinctly difficult-to-treat population
- Cretostimogene grenadenorepvec is an oncolytic immunotherapy with dual mechanisms of action, selectively replicating in and lysing cancer cells while amplifying anti-tumor immune response
- BOND-003 is a pivotal Phase 3 trial designed to evaluate cretostimogene in patients with BCG-UR NMIBC
- We report Cohort C efficacy and safety, with subgroup analyses of patients in heavily pre-treated population subgroups.

METHODS

- Eligible patients had HR BCG-UR NMIBC with CIS +/- Ta/T1
- Subgroups identified based on prior treatment exposure prior to BOND-003 enrollment:
 - Second-Line: patients diagnosed with BCG-UR who received an additional therapy after adequate BCG
 - Prior Intervening Chemotherapy: adjuvant IVE chemotherapy before or after adequate BCG
- Response assessments: serial cystoscopy, urine cytology, CT urogram/MRU, mandatory mapping biopsy
- All responses centrally confirmed; Primary endpoint: CR at any time



RESULTS

Efficacy Evaluable Population

- As of the 23 Jun 2025 data cut:
- 110 efficacy evaluable patients
- Majority male (74%), white (62%), >65 years old (83%)
- Median follow-up: 25.8 months; CR rate at any time: 75.5% (83/110)

Safety Profile

Preferred Term (MedDRA v.26.1)	Cretostimogene (n=112)	
	Any Grade (%)	Grade ≥3
Patients with ≥1 TRAE	71 (63.4%)	0 (0)
Treatment-Related AE reported in >20% patients		
Bladder Spasm	28 (25%)	0 (0)
Pollakiuria	25 (22.3%)	0 (0)
Urgency	23 (20.5%)	0 (0)

- Most AEs Grade 1-2; median 1-day (IQR 0-7 days) time to TRAE resolution
- High treatment compliance: no treatment-related discontinuations; few missed (1.8%) or delayed (7.1%) doses

Abbreviations: AE: adverse event; ASCO: American Society of Clinical Oncology; AUA: American Urological Association; BCG: Bacillus Calmette-Guérin; CFS: cystectomy-free survival; CIS: carcinoma in situ; CR: complete response; DOR: duration of response; HG: high grade; HR: high-risk; IVE: intravesical; NMIBC: non-muscle invasive bladder cancer; RC: radical cystectomy; SUO: Society of Urologic Oncology; TRAE: treatment-related adverse event; UR: unresponsive; UTUC: upper tract urothelial carcinoma; MIBC: muscle-invasive bladder cancer

BOND-003

COHORT C

BCAN

20 Years of Impact


Strong Efficacy in Heavily Pre-Treated and Second Line Population

Well-Tolerated Safety Profile

RESULTS

Second Line and Prior Intervening Chemotherapy

- 23/110 (21%) patients: Second-Line BCG-UR
 - CR rate at any time: 69.6% (16/23)
- 34/110 (31%) patients Prior Intervening Chemotherapy, with
 - ≥1 course of IVE gemcitabine (11/34; 32%)
 - IVE gemcitabine-docetaxel (16/34; 47%)
 - CR rate at any time: 64.7% (22/34)



DISCUSSION


- This analysis focuses on two challenging HR subgroups: Second-Line BCG-UR disease, an indication recently recognized by the FDA,³ and a broader population of heavily-pretreated patients
- Cretostimogene demonstrated strong CR rates in both heavily pretreated subgroups, supporting its potential as a bladder-sparing option even in heavily pre-treated NMIBC populations
- These findings may reflect cretostimogene's dual mechanism of action which selectively targets cancer cells, in contrast to the non-specific mechanisms of BCG and chemotherapy

Contact Information: Mark D. Tyson, MD, MPH: Tyson.Mark@mayo.edu

Acknowledgements: Pat Keegan, MD; Jee-Hyun Kim, PhD; Leah Rider, PhD; Anastasiia Shermolovych, MPharm; Angelica Craighead, CCRP; Shelja Patel, PharmD, Sarah D. Hohl, PhD, and Vijay Kasturi, MD

References: 1 NCCN Bladder Cancer Guidelines; 2026, 2 AUA/SUO NMIBC Guidelines; 2026, 3 Remalda Therapeutics, Inc. Press Release, Jan 12, 2026


#339

MAYO
CLINIC

BOND-003 COHORT C: OUTCOMES OF CRETOSTIMOGENE IN HEAVILY PRE-TREATED AND SECOND-LINE HIGH-RISK BCG UNRESPONSIVE NMIBC WITH CIS

- Phase 3 registrational trial
- Patients with HR BCG-UR NMIBC with CIS +/- Ta/T1
- Primary endpoint: CR at any time
- 23/110 (21%) patients: Second-Line BCG-UR
- 34/110 (31%) patients Prior Intervening Chemotherapy

Complete Response Rate at Any Time (%)



Efficacy data cutoff as of 23JUN2025



For individual reference only. The information accessed through this QR code is intended solely for individual reference and should not be altered, modified, or reproduced in any way.



THE LANCET **Oncology**